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Abstract The chemokine monocyte chemoattractant protein-1
is a potent chemoattractant for monocytes. Monocyte chemoat-
tractant protein-1 is produced by vascular endothelial cells during
inflammatory diseases such as atherosclerosis. In this study, we
examined the effects of a thiazolidinedione on monocyte
chemoattractant protein-1 expression in human vascular en-
dothelial cells. In human vascular endothelial cells, interleukin-
1L and tumor necrosis factor-K induced endogenous monocyte
chemoattractant protein-1 protein secretion, mRNA expression
and promoter activity. The thiazolidinedione inhibited these
effects. In summary, our results indicated that the suppression of
the expression of monocyte chemoattractant protein-1 can be
accomplished by thiazolidinedione treatment, raising the possi-
bility that thiazolidinedione may be of therapeutic value in the
treatment of diseases such as atherosclerosis.
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1. Introduction
Chemokines are a family of small molecular mass proteins
(8^16 kDa) that was originally classi¢ed based on the conser-
vation of a four cysteine motif and on the ability to cause the
directed migration of leukocytes in vitro [1]. The recruitment
of monocytes and lymphocytes into sites of atherosclerotic
lesions is mediated, in part, by chemotactic cytokines or che-
mokines [2]. Monocytes have been shown to be selectively
attracted to speci¢c chemokines that predominantly belong
to the C-C family of chemoattractants which includes human
monocyte chemoattractant protein-1 (MCP-1). MCP-1 is a
76 amino acid chemokine thought to be the major chemo-
tactic factor for monocytes [3]. Several reports indicated
that MCP-1 is one of the key factors initiating the in£amma-
tory process of atherogenesis [2^4]. MCP-1 is expressed by a
variety of cell types including monocytes, smooth muscle cells
and human vascular endothelial cells (HUVECs) in response
to several di¡erent stimuli including interleukin (IL)-1L and
tumor necrosis factor (TNF)-K [5]. Recently, MCP-1 was
found in macrophage-rich areas of atherosclerotic lesions
[4,6].
Thiazolidinediones (TZDs), which are known to have po-
tent enhancing e¡ects on insulin sensitivity, have been devel-
oped for the treatment of non-insulin-dependent diabetes mel-
litus [7]. TZDs can speci¢cally and powerfully block the
action of TNF-K to inhibit insulin signaling, suggesting one
plausible mechanism for its action in improving insulin resist-
ance [8]. It has also been found that TZDs are a high a⁄nity
ligand for the peroxisome proliferator-activated receptor-Q
(PPAR-Q), which belongs to a nuclear receptor superfamily
[9]. Two groups recently reported that PPAR-Q activators
such as 15-deoxy-v12;14 prostaglandin J2 and TZDs can inhib-
it the production of several in£ammatory cytokines including
IL-1L and TNF-K by phorbol 12-myristate 13-acetate and
interferon-Q-activated macrophages in vitro [10,11].
In this study, we examined the e¡ects of a TZD on expres-
sion of MCP-1 in response to IL-1L and TNF-K in HUVECs.
Our results demonstrated that the expression of MCP-1 was
inhibited by the TZD at the transcriptional level.
2. Materials and methods
2.1. Materials
The TZD was provided by Sankyo Pharmaceuticals (Tokyo, Ja-
pan). Wy14643 was from Cayman (Ann Arbor, MI, USA). TNF-K
and IL-1L were obtained from Research Biochemicals International
(Natick, MA, USA). All other reagents were of analytical grade.
2.2. Cell culture
HUVECs were purchased from Clonetics (San Diego, CA, USA)
and used between passages 1^6. HUVECs were maintained in M199
(Sigma) supplemented with 10% heat-inactivated fetal bovine serum
(Dainippon Pharmaceutical, Tokyo, Japan), 100 U/ml penicillin and
100 mg/ml streptomycin in a humidi¢ed atmosphere containing 5%
CO2 at 37‡C. When 80% con£uent, the cells were washed twice and
incubated with serum-free M199 for 12 h before being stimulated with
IL-1L or TNF-K. An hour after cytokine stimulation, cells were
treated with TZD or 100 WM Wy14643 for 12 or 24 h.
2.3. RNA isolation and Northern blot analysis
A single-step acid guanidinium thiocyanate-phenol-chloroform ex-
traction technique [12] was used to isolate total RNA from HUVECs
treated with cytokines and/or TZD for 24 h. The separation of the
RNA samples, transfer to a membrane and hybridization with human
MCP-1 cDNA were described previously [13]. The 183 bp cDNA of
human MCP-1 was synthesized by a polymerase chain reaction (PCR)
method using reverse transcribed RNA as previously described [14].
Primers used for PCR were as follows, sense: 5P-AATAGGAA-
GATCTCAGTGCA-3P, antisense: 5P-TCAAGTCTTCGGAGTTTG-
GG-3P corresponding to the published sequences [15]. The probe used
in the hybridization was radiolabelled with [32P]dCTP (3000 Ci/mmol)
using a random priming kit (TaKaRa Biomedicals, Tokyo, Japan).
Blots were also probed with human L-actin to assess equal loading of
samples [16]. After autoradiography at room temperature for 24 h,
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hybridization signals were detected using a Bioimaging Analyzer (BAS
1000, Fuji Photo Film, Tokyo, Japan).
2.4. Transfection of HUVECs and luciferase reporter gene assay
To con¢rm the transcriptional regulation by TZD of MCP-1 ex-
pression, we used a promoter construct of the MCP-1 gene. The
reporter contains the human MCP-1 gene sequence spanning the re-
gion from 3515 to +44 as the published sequence [17], was ampli¢ed
by PCR and cloned into the luciferase reporter gene (pMCP-LUC).
Puri¢ed reporter plasmid was transfected into HUVECs (at 60% con-
£uence) by conventional cationic liposome transfection methods
(Lipofectamine, Life Technologies, Gaithersburg, MD, USA). 2 Wg
of Rous sarcoma virus L-galactosidase was added to all transfections
to monitor the e⁄ciency of DNA uptake by HUVECs [18]. All assays
were corrected for L-galactosidase activity and the total amounts of
protein per reaction were identical. Transfected cells were maintained
in control media containing 1 ng/ml IL-1L or 10 ng/ml TNF-K with or
without TZD for 24 h. Transfected cells were harvested and an ali-
quot of the cytoplasmic fraction was taken for the measurement of
L-galactosidase activity [18]. 20 Wl aliquots were taken for the lucifer-
ase assay, which was performed according to the manufacturer’s in-
structions (ToyoInk, Tokyo, Japan).
2.5. MCP-1 enzyme-linked immunosorbent assay (ELISA)
The levels of immunoreactive MCP-1 were quanti¢ed using a com-
mercially available sandwich type ELISA (R and D Systems, Minne-
apolis, MN, USA). ELISA plates were coated with a speci¢c murine
monoclonal antibody (mAb) against human MCP-1. Dilutions of cell-
free supernatants were added in duplicate, followed by the addition of
a second horseradish peroxidase-conjugated goat polyclonal Ab
against MCP-1. After washing to remove any unbound Ab-enzyme
reagent, a substrate solution (a 1:1 solution of hydrogen peroxide and
tetramethylbenzidine) was added to the wells. The color development
was stopped with 2 N sulfuric acid and the intensity of the color was
measured at 540 nm on a spectrophotometer. This ELISA is sensitive
to 2.5 pg/ml MCP-1 and it has an intra-assay coe⁄cient of variation
of 6 0.5% and an inter-assay coe⁄cient of variation of 6 10%.
2.6. Statistical analysis
Statistical comparisons were made by one-way analysis of variance
and Student’s t-test, with P6 0.05 considered signi¢cant.
3. Results
3.1. TZD blocks the IL-1L- and TNF-K-mediated stimulation
of MCP-1 secretion in HUVECs
Several studies have shown that IL-1L and TNF-K stimu-
late MCP-1 secretion by HUVECs [6,19]. As expected, TNF-K
and IL-1L each stimulated the MCP-1 secretion in a time-
dependent manner (Fig. 1A). The maximal e¡ect was ob-
served at 10 ng/ml TNF-K and 1 ng/ml IL-1L in HUVECs
(data not shown). When cells were pretreated with 10 WM
TZD, the MCP-1 secretion by IL-1L-treated HUVECs was
inhibited. TZD also inhibited MCP-1 secretion by TNF-K-
treated HUVECs. This inhibitory e¡ect of TZD was dose-
dependent. Doses of TZD as low as 10 nM reduced the
MCP-1 release in 24 h cultures stimulated with 1 ng/ml IL-
1L and 10 ng/ml TNF-K (Fig. 1B). In contrast, Wy14643,
which acts through the related PPAR-Q, had no activity to
inhibit MCP-1 secretion by cytokine-treated HUVECs.
3.2. The e¡ect of TZD on MCP-1 mRNA in HUVECs
Using a human MCP-1-speci¢c probe, we performed
Northern blot analysis and detected a signal as the expected
size [15]. As shown in Fig. 2, both IL-1L and TNF-K stimu-
lated the expression of MCP-1 in HUVECs, consistent with
previous reports [6,19]. TZD suppressed the induction of the
MCP-1 mRNA in HUVECs treated with IL-1L and TNF-K.
In contrast, TZD had no e¡ect on the steady-state expression
of L-actin in the cells. It had no e¡ect on the cell viability, as
determined by the cell number and cell morphology (data not
shown).
Fig. 1. Inhibition of cytokines-induced MCP-1 protein secretion by
TZD in HUVECs. (A) E¡ects of TZDs and Wy14643 on the induc-
tion of MCP-1 by IL-1L and TNF-K. HUVECs were co-incubated
with either 10 WM TZD or 100 WM Wy14643 in medium containing
1 ng/ml IL-1L or 10 ng/ml TNF-K for 12 or 24 h. MCP-1 release
into the medium was measured by an ELISA. Lane 1, control; lane
2, IL-1L ; lane 3, IL-1L and TZD; lane 4, TNF-K ; lane 5, TNF-K
and TZD; lane 6, IL-1L and Wy14643; lane 7, TNF-K and
Wy14643. (B) Dose-response of TZD on MCP-1 release. HUVECs
were co-incubated with IL-1L (1 ng/ml) or TNF-K (10 ng/ml) and
various doses of TZD in combination for 24 h. The asterisk and
N.S. denote a signi¢cant di¡erence (P6 0.05) and not a signi¢cant
di¡erence, respectively. The error bars show S.E.M. of four determi-
nations.
FEBS 22219 25-6-99
K. Murao et al./FEBS Letters 454 (1999) 27^3028
3.3. E¡ects of TZD on the human MCP-1 promoter in
HUVECs treated with IL-1L and TNF-K
The response of pMCP-LUC to 1 ng/ml of IL-1L and 10
ng/ml of TNF-K in HUVECs is shown in Fig. 3. Consistent
with the observed changes in the level of endogenous MCP-1
mRNA, 1 ng/ml IL-1L stimulated promoter activity. In the
presence of both IL-1L and TZD, TZD inhibited the IL-1L-
induced MCP-1 promoter activity in HUVECs. In contrast,
TZD had a less, but still a signi¢cant, e¡ect on the TNF-K-
induced MCP-1 promoter activity in HUVECs. These ¢ndings
indicate that the activity of the human MCP-1 promoter in
HUVECs following exposure to the cytokines and TZD re-
£ected the endogenous expression of MCP-1 mRNA.
4. Discussion
In this study, we examined the e¡ects of TZD on MCP-1
expression in response to cytokines in HUVECs. Interest in
this topic stems from the clinical observation that the secre-
tion of a monocyte-speci¢c chemoattractant by cytokine-acti-
vated endothelial cells provides part of the basis for the accu-
mulation of monocytes at sites of vascular injury and
in£ammation such as atherosclerosis [6,19]. MCP-1 is chemo-
tactic for monocytes but not for neutrophils and seems to be
the major chemotactic molecule generated within the vessel
wall such as macrophage-rich areas of the atherosclerotic le-
sion [1].
The expression of MCP-1 is observed in a variety of cell
types including monocytes, vascular smooth muscle cells and
HUVECs in response to several di¡erent stimuli including IL-
1L and TNF-K [5,6,19]. In addition to inducing chemoattrac-
tion by means of MCP-1, IL-1Land TNF-K also cause an
increased adhesion of monocytes to the endothelial cell sur-
face, probably by including the expression of speci¢c endothe-
lial monocyte adhesion molecules [20]. Recently, Boring et al.
generated mice that lack CCR2, the receptor for MCP-1, and
crossed them with apolipoprotein (apo) E-null mice which
develop severe atherosclerosis, showing that the selective ab-
sence of CCR2 decreases atherosclerotic lesion formation
markedly in apoE3/3 mice [21]. These results provide strong
evidence for a direct e¡ect of MCP-1 in macrophage recruit-
ment and atherogenesis.
When HUVECs were exposed to the cytokine IL-1L or
TNF-K, the cytokine stimulated not only MCP-1 mRNA ex-
pression and protein secretion but also MCP-1 promoter ac-
tivity. Although the exact mechanism of the cytokine-medi-
ated induction of MCP-1 expression is unknown, our present
results indicate that the inhibition of cytokine-mediated MCP-
1 expression by TZDs was partially regulated at the transcrip-
tional level. The promoter region of the human MCP-1 gene
has been cloned, sequenced and shown to contain putative
consensus binding sites for a variety of transcription factors
[17]. IL-1L-induced MCP-1 gene expression in human endo-
thelial cells depends on the cooperative action of NF-kB and
AP-1 [22]. PPAR-Q, one of the transcriptional factors, is
thought to be the functional receptor for the TZDs [9], since
the activation of PPAR-Q by a TZD may modulate the acti-
vation of several transcriptional factors in response to cyto-
kines. Further examinations are necessary to determine the
transcriptional regulation of the MCP-1 gene by TZD and
cytokines.
In summary, we examined the e¡ects of TZD on MCP-1
expression in response to IL-1L and TNF-K in HUVECs. The
results indicate that the suppression of the MCP-1 expression
can be accomplished by TZD treatment, suggesting that TZD
has a therapeutic value in the treatment of human diseases
such as atherosclerosis in which MCP-1 plays an important
role.
References
[1] Schall, T.J. and Bacon, K.B. (1994) Curr. Opin. Immunol. 6,
865^873.
[2] Terkeltaub, R., Boisvert, W.A. and Curtiss, L.K. (1998) Curr.
Opin. Lipidol. 9, 397^405.
[3] Navab, M., Imes, S.S., Hama, S.Y., Hough, G.P., Ross, L.A.,
Bork, R.W., Valente, A.J., Berliner, J.A., Drinkwater, D.C.,
Fig. 2. TZD inhibits MCP-1 mRNA expression in cytokine-treated
HUVECs. 10 Wg of total RNA isolated from HUVECs treated for
24 h with 1 ng/ml IL-1L or 10 ng/ml TNF-K with/without 10 WM
TZD was separated by agarose gel electrophoresis and transferred
to a membrane. The blots were hybridized with the encoding region
of human MCP-1 [32P]cDNA and human L-actin [32P]cDNA that
was used as a control for equal RNA loading and transfer. Lane 1,
control; lane 2, IL-1L ; lane 3, IL-1L and TZD; lane 4, TNF-K ;
lane 5, TNF-K and TZD. An identical experiment independently
performed gave similar results.
Fig. 3. The e¡ect of TZD on MCP-1 promoter activity in HUVECs.
HUVECs were transfected with 10 Wg of pMCP-LUC and treated
with 1 ng/ml IL-1L (A) or 10 ng/ml TNF-K(B) and/or 10 WM TZD
for 24 h prior to cell harvest. All assays were corrected for L-galac-
tosidase activity and total amounts of protein per reaction were
identical. The results are expressed as relative luciferase activities
compared to control cells arbitrarily set at 100. Each data point
shows the mean and S.E.M. (n = 4) of separate transfections. Lane
1, control; lane 2, IL-1L ; lane 3, IL-1L and TZD; lane 4, TNF-K ;
lane 5, TNF-K and TZD. The asterisk denotes a signi¢cant di¡er-
ence (P6 0.05).
FEBS 22219 25-6-99
K. Murao et al./FEBS Letters 454 (1999) 27^30 29
Laks, H. and Fogelman, A.M. (1991) J. Clin. Invest. 88, 2039^
2046.
[4] Yla-Herttuala, S., Lipton, B.A., Rosenfeld, M.E., Sarkioja, T.,
Yoshimura, T., Leonard, E.J., Witztum, J.L. and Steinberg, D.
(1991) Proc. Natl. Acad. Sci. USA 88, 5252^5256.
[5] Leonard, E.J. and Yoshimura, T. (1990) Immunol. Today 11, 97^
101.
[6] Rollins, B.J., Yoshimura, T., Leonard, E.J. and Pober, J.S.
(1990) Am. J. Pathol. 136, 1229^1233.
[7] Saltiel, A.R. and Olefsky, J.M. (1996) Diabetes 45, 1661^1669.
[8] Peraldi, P., Xu, M. and Spiegelman, B.M. (1997) J. Clin. Invest.
100, 1863^1869.
[9] Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison,
W.O., Willson, T.M. and Kliewer, S.A. (1995) J. Biol. Chem.
270, 12953^12956.
[10] Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. and Glass, C.K.
(1998) Nature 391, 79^82.
[11] Jiang, C., Ting, A.T. and Seed, B. (1998) Nature 391, 82^86.
[12] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 156^
159.
[13] Murao, K., Sato, M., Mizobuchi, M., Niimi, N., Ishida, T. and
Takahara, J. (1994) Endocrinology 134, 418^423.
[14] Mizobuchi, M., Murao, K., Takeda, R. and Kakimoto, Y. (1994)
J. Neurochem. 62, 322^328.
[15] Furutani, Y., Nomura, H., Notake, M., Oyamada, Y., Fukui, T.,
Yamada, M., Larsen, C.G., Oppenheim, J.J. and Matsushima, K.
(1989) Biochem. Biophys. Res. Commun. 159, 249^255.
[16] Murao, K., Sato, M., Imachi, H., Ohe, H., Nagai, M., Niimi, M.,
Ishida, T. and Takahara, J. (1998) Endocr. J. 45, 399^405.
[17] Shyy, Y.J., Li, Y.S. and Kolattukudy, P.E. (1990) Biochem. Bio-
phys. Res. Commun. 169, 346^351.
[18] Murao, K., Wada, Y., Nakamura, T., Taylor, A.H., Mooradian,
A.D. and Wong, N.C.W. (1998) J. Biol. Chem. 273, 18959^
18965.
[19] Sica, A., Wang, J.M., Colotta, F., Dejana, E., Mantovani, A.,
Oppenheim, J.J., Larsen, C.G., Zachariae, C.O. and Matsushima,
K. (1990) J. Immunol. 144, 3034^3038.
[20] Bevilacqua, M.P., Pober, J.S., Wheeler, M.E., Cotran, R.S. and
Gimbrone Jr., M.A. (1985) J. Clin. Invest. 76, 2003^2011.
[21] Boring, L., Gosling, J., Cleary, M. and Charo, I.F. (1998) Nature
394, 894^897.
[22] Martin, T., Cardarelli, P.M., Parry, G.C., Felts, K.A. and Cobb,
R.R. (1997) Eur. J. Immunol. 27, 1091^1097.
FEBS 22219 25-6-99
K. Murao et al./FEBS Letters 454 (1999) 27^3030
